Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials

Several vaccine candidates to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) have entered or will soon enter large-scale, phase 3, placebo-controlled randomized clinical trials. To facilitate harmonized evaluation and com...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Intern Med
Main Authors: Mehrotra, Devan V., Janes, Holly E., Fleming, Thomas R., Annunziato, Paula W., Neuzil, Kathleen M., Carpp, Lindsay N., Benkeser, David, Brown, Elizabeth R., Carone, Marco, Cho, Iksung, Donnell, Deborah, Fay, Michael P., Fong, Youyi, Han, Shu, Hirsch, Ian, Huang, Ying, Huang, Yunda, Hyrien, Ollivier, Juraska, Michal, Luedtke, Alex, Nason, Martha, Vandebosch, An, Zhou, Honghong, Cohen, Myron S., Corey, Lawrence, Hartzel, Jonathan, Follmann, Dean, Gilbert, Peter B.
Formato: Artigo
Idioma:Inglês
Publicado: American College of Physicians 2020
Assuntos:
Research and Reporting Methods
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7596738/
https://ncbi.nlm.nih.gov/pubmed/33090877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7326/M20-6169
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares